- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01444235
Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery
A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N Versus Custodiol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Essen, Germany, 45147
- Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen
-
Heidelberg, Germany, 69120
- Abt. Herzchirugie, Universitätsklinikum Heidelberg
-
Jena, Germany, 07740
- Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena
-
Leipzig, Germany, 04289
- Herzzentrum Leipzig GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The study population will be selected from patients of either sex with coronary artery disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery.
- Patients >/=35 and </=80 years of age
- Male or female with 2 or 3 vessel coronary disease, who are scheduled for elective CBP surgery for coronary revascularisation
Presence of definite CAD for which surgical intervention is deemed necessary, without evidence of ongoing infarction.
Patients with unstable angina can be included as long as there is no objective (negative cardiac isoenzymes in the immediate six hours preceding CABG, current intravenous use of nitrate therapy) or subjective (absence of prolonged symptoms suggestive of coronary insufficiency that do not respond to pharmacologic intervention) evidence of myocardial necrosis.
- Eligibility for Swan-Ganz-Catheter
- Able to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study
- No evidence of severe organic or psychiatric disease by history or physical examination
- No history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or no any history of drug abuse or addiction within 12 months of study enrollment.
Exclusion Criteria:
- Patients undergoing valve repair or replacement
- History of recent (< 6 weeks) Q-wave myocardial infarction
- Left ventricular ejection fraction < 35% (as assessed by any one of the following: contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)
- Patients on intra-aortic balloon devices or with history of previous coronary artery bypass surgery
- Pregnant or lactating patients
- Patients who have participated in any other investigational studies within 30 days previous to enrollment
- Patients in cardiogenic shock (defined as a systolic BP < 90 mmHg for over one hour despite inotropic and chronotropic support)
- Patients with severe chronic obstructive lung disease (FEV1 < 50%)
- Previous cardiac valvular disease (clinical relevant)
- Dialysis or creatinine > 2 mmol/L
- BMS-Stent < 4 weeks
- DES-Stent < 6 month
- Guidance depended Plavix therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Custodiol
After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
|
Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
|
EXPERIMENTAL: Custodiol-N
After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
|
Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CK-MB area under the curve within 24 hours
Time Frame: Up to 24 hours after the aortic clamp release
|
Measurements will be carried out at the following timepoints: 4,8,12,16,20,24 hours (± 30 min) after release of the aortic cross clamp
|
Up to 24 hours after the aortic clamp release
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Catecholamine requirement
Time Frame: 24 hours (cumulative dose)
|
Catecholamine requirement on surgical ICU within 24 hours
|
24 hours (cumulative dose)
|
CK-MB peak
Time Frame: Up to day 5
|
CK-MB peak on the days 2, 3, 4 and 5 after removal of aortic cross clamp
|
Up to day 5
|
Mortality any time during post-op through Day 30
Time Frame: Up to Day 30
|
Mortality will be documented at any time during post-op through Day 30
|
Up to Day 30
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gabor Szabo, Prof. Dr., Department of Cardiac Surgery of University of Heidelberg
- Principal Investigator: Nikolaus Pizanis, Dr., Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen
- Principal Investigator: Florian Wagner, Dr., Klinik für Herz- und Gefäßchirurgie, Universitäts-Krankenhaus Eppendorf
- Principal Investigator: Thorsten Doenst, Prof. Dr., Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena
- Principal Investigator: Martin Misfeld, Dr., Herzzentrum Leipzig GmbH, Klinik für Herzchirurgie
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-N-CSM-III/01/08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease (CAD)
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Assiut UniversityRecruitingCAD - Coronary Artery DiseaseEgypt
-
Johann Wolfgang Goethe University HospitalActive, not recruiting
-
Sinotau Pharmaceutical GroupCompletedCoronary Artery Disease (CAD)China
-
Astellas Pharma IncCompletedCoronary Artery Disease (CAD)United States
-
GE HealthcareCompletedCoronary Artery Disease (CAD)United States
-
Eli Lilly and CompanyDaiichi Sankyo Co., Ltd.TerminatedCoronary Artery Disease (CAD)United States, Germany
-
Anthera PharmaceuticalsCompletedCoronary Artery Disease (CAD)United States, Ukraine
-
GE HealthcarePharmaceutical Product Development, LLCCompletedCoronary Artery Disease (CAD)United States, Germany, Switzerland, Canada, Netherlands, France, Finland
-
Columbia UniversityTerminatedCoronary Artery Disease (CAD)United States
Clinical Trials on Custodiol
-
Dr. F. Köhler Chemie GmbHCompletedAortic Valve Disease | Coronary Artery Disease (CAD)Germany
-
Dr. F. Köhler Chemie GmbHCompletedHeart FailureAustria, Germany
-
Dr. F. Köhler Chemie GmbHActive, not recruiting
-
Dr. F. Köhler Chemie GmbHRecruitingKidney Failure | Liver Failure, Chronic | Kidney-Pancreas FailureAustria
-
Centre Hospitalier Universitaire de Saint EtienneJazz Pharmaceuticals; Association AIRE (FR)Completed
-
Rigshospitalet, DenmarkLundbeck FoundationCompleted
-
King Faisal Specialist Hospital & Research Centre...CompletedCongenital Heart DiseaseSaudi Arabia
-
Fayoum University HospitalCompletedCardioplegia Solution Adverse ReactionEgypt
-
Scientific Institute San RaffaeleCompleted
-
Republican Scientific and Practical Center for...CompletedLiver Transplantation | Early Allograft Dysfunction | Ischemic Reperfusion Injury | HyperfibrinolysisBelarus